Research Article
Volume 3 Issue 1 - 2015
Low Plasma Vitamin D (25-Hydroxycholecalciferol) in Children and Adolescents Diagnosed with Cancer: A Case-Control Study
Ilenia Paciarotti1, R Revuelta Iniesta2, Jane M McKenzie3, Celia Brand4, Richard FM Chin5, Mark Brougham6 and David C Wilson7*
1,2Department of Dietetics, Nutrition and Biological Health Sciences, Queen Margaret University, Edinburgh, and Child Life and Health, University of Edinburgh, Edinburgh, United Kingdom
3Department of Dietetics, Nutrition and Biological Health Sciences, Queen Margaret University, Edinburgh, United Kingdom
4,5Department of Neurology, Royal Hospital for Sick Children, Edinburgh, United Kingdom
6Department of Haematology and Oncology, Royal Hospital for Sick Children, Edinburgh, United Kingdom
7Department of Paediatric Gastroenterology and Nutrition, Royal Hospital for Sick Children, Edinburgh, United Kingdom
*Corresponding Author: Prof. David C Wilson, Child Life and Health, University of Edinburgh, 20 Sylvan Place, Edinburgh EH9 1UW, United Kingdom.
Received: November 24, 2015; Published: December 12, 2015
Citation: Ilenia Paciarotti., et al. “Low Plasma Vitamin D (25-Hydroxycholecalciferol) in Children and Adolescents Diagnosed with Cancer: A Case-Control Study”. EC Nutrition 3.1 (2015): 513-520.
Introduction: Children and young people with cancer are less likely to spend time outdoors and they may also have a limited dietary intake. In addition, some cancer treatments can increase vitamin D catabolism.
Objectives: This study aimed to investigate if there was an increased risk of poor vitamin D status in newly diagnosed childhood cancer patients compared to healthy controls in Scotland.
Methods: Plasma 25 (OH) D was measured in children and adolescents during initial cancer treatment and compared to 33 healthy controls. Vitamin D deficiency was classified as plasma 25 (OH) D < 25 nmol/l, with a plasma 25 (OH) D of 25-49 nmol/l classified as insufficient.
Results: Forty-one patients (median age 3.8 years, IQR 1.9-8.0) were diagnosed with cancer, 63% were male. Twenty-three (56 %) had solid tumours, 18 (44%) had haematological cancers. Median (IQR) plasma 25 (OH) D at recruitment was 37.0 nmol/l (23.7-58.2). Ten patients (24%) had vitamin D deficiency and 17 (41%) patients were classified as insufficient. The median (IQR) plasma 25 (OH) D in the control group (n = 33) was 37.5 nmol/l (29.0-58.0). Six controls (18%) had vitamin D deficiency and 14 (42%) were classified as having insufficient results. Plasma 25 (OH) D did not differ (p > 0.05) between the patients and the controls.
Conclusions: Almost three in four Scottish children treated for cancer had vitamin D deficiency or insufficiency; there was no increased risk of poor vitamin D status compared to healthy controls. Assessment of vitamin D status at diagnosis and in response to the course of treatment appears necessary to optimise nutritional management.
Keywords: Children; Cancer; Vitamin D; Nutrition screening
Abbreviation: ICCC-3: The International Classification of Childhood Cancer, third edition; CNS: Central Nervous System; NHS: National Health Service; NS: Nutrition Support; PTH: Parathyroid hormone; RHSC: Royal Hospital for Sick Children
Vitamin D is currently attracting a great deal of scientific and media attention. Due to lack of sunlight exposure plus very few foods being fortified with vitamin D in the UK, children and adults are at high risk of being deficient or insufficient, especially in high latitude countries [1,2]. Vitamin D deficiency causes bone mass loss [3,4] with detrimental effects on bone growth and development, particularly important in children. Moreover, skeletal problem such as osteoporosis, reduced bone mass density and fractures, are a well-known issue in children with cancer [5-8] and vitamin D insufficiency has been suggested as a potential risk factor [5,9-12].
Children treated for cancer have an increased risk of poor vitamin D status because they may have reduced vitamin D3 synthesis on the skin (limited time spent outdoors, need to protect the skin from UV rays due to the photosensitivity caused by some treatments), or reduced dietary intake or absorption as consequence of drug related side effects and liver and chemotherapy related kidney damage. Furthermore, patients treated for leukaemia may have a higher risk of deficiency [13] due to the increased vitamin D catabolism caused by steroids [14]. Therefore, given the increased risk for poor vitamin D status in childhood cancer patients and the pivotal role of vitamin D in growth and development it may be essential to maintain adequate vitamin D status from diagnosis throughout treatment. This case control study aimed to investigate (i) the vitamin D status of newly diagnosed childhood cancer patients; (ii) Whether there is an increased risk of poor vitamin D status in newly diagnosed childhood cancer patients compared to healthy childhood controls within the same geographical population.
Materials and Methods
Patient Selection and recruitment
In this study inclusion criteria included: (i) children under the age of 18 years,(ii) a cancer diagnosis according to The International Classification of Childhood Cancer, third edition (ICCC-3) [15] or Langerhans cell histiocytosis tumours, (iii) diagnosed between August 2010 and March 2013 (iv) attending the regional centre for Haematology and Oncology at the Royal Hospital for Sick Children (RHSC), Edinburgh (SE Scotland service - NHS Lothian, NHS Borders, NHS Fife, NHS Tayside) and of high northerly latitude at 55°N. Exclusion criteria were: (i) children on palliative care, (ii) and patients with unavailable plasma 25(OH)D result.
The study had ethical approval from NHS Scotland. The child and the parents or guardians were provided with full written information regarding the project to give them the opportunity for ‘informed consent’. Patient’s data remained confidential and all data was anonymised.
Anonymised control data was obtained from a case-control study on Vitamin D in children with epilepsy compared to children without epilepsy. Controls were recruited from randomly invited healthy children who were attending the RHSC Emergency Department and who were having blood tests done as part of their assessment. At enrolment, control volunteers had 25(OH) D, parathyroid hormone (PTH), calcium, phosphate and magnesium checked; volunteers were invited for reassessment at six months post-baseline.
Data Collection
Patients were recruited as soon as diagnosis was confirmed (the duration of the study was 3 years). Clinical information including diagnosis, length of treatment and the need for nutrition support and demographic data, including age, gender and ethnicity were collected from medical and dietetic notes. Due to the limited numbers available in the study and the wide range of childhood cancer diagnosis, the cohort was grouped according to the wider definition of solid tumours (Lymphomas, CNS, Neuroblastoma, Renal, Bone, Soft tissue sarcomas, Germ cell tumour and Langerhans cell histiocytosis) and haematological cancers (Leukaemias). Measurements were taken at recruitment. Summer months were defined as the beginning of April to the end of September [16] Blood was taken by NHS staff for 25(OH) D, PTH, calcium, phosphate and magnesium when the patient had venepuncture for routine blood test or therapy.
Calcium, phosphate and magnesium were analysed using the Abbott Architect c8000 by the biochemistry department, Royal Hospital of Sick Children, PTH was analysed using the Immulite 2000 Intact PTH technique by the biochemistry department, Royal Infirmary of Edinburgh and plasma 25(OH) D was analysed using the liquid chromatography tandem mass spectrometry technique by the Clinical Chemistry Department, Royal Infirmary of Glasgow using standard techniques. Due to the limited sample size the data were combined to look at differences between the control and cancer cohort. For the controls, when both winter and summer samples were available, the average was used for statistical analysis. The results were compared with the reference values recommended in the British Paediatric and Adolescent bone group guidelines, which defines 25 (OH)D levels suboptimal (50-75 nmol/L), insufficient (25-50 nmol/L) and deficient (< 25 nmol/L).
Data analysis
The data was analysed using The Statistical Package for Social Studies (IBM-SPSS for Windows Statistics, version 19 UK).The data were tested for normal distribution by the Shapiro-Wilk Test. The results are presented as mean (± SD) for normally distributed data and median (IQR) when not normally distributed. Descriptive statistics were used to assess vitamin D status, plasma calcium, phosphate, magnesium status and parathyroid function (aim i). Comparison within the same group was carried out using the Wilcoxon signed-rank test. Comparison between control and childhood cancer groups was carried out using the Mann-Whitney test (aim ii). STROBE guidelines were followed for the presentation of the data (
A flow diagram of the cohort is shown in Figure 1; there was not a difference in gender distribuition, ethicity or age at diagnosis (p > 0.05) between the participants and non-participants. A total of 41 (59%) patients were included in the study with median (IQR) age at diagnosis 3.8 (1.9-8.0) years; 73% (n = 30) of the total cohort was male. Twenty-three patients (56%) had solid tumours and 18 (44%) had hematological cancers. All patients were white. Due to the time lapse between approaching the families and recruitment, all the participants were on cancer treatment at the time the blood was collected (mean time on treatment 14.6 days; IQR 7.3-21.9). Of note 13 patients (72%) in the hematological group were treated with steroids.
Figure 1: Flow diagram showing all children and young people in cohort.
There were 33 healthy volunteer control subjects (age median 7.1, IQR 4.7–9.08); 45% (n = 15) were male. Thirty-one (94%) were white and 2(6%) were non-white.
Fourteen patients (34%) were on some type of nutrition support ( providing 0.7 ug vitamin D/100 kcal to 1.9 vitamin D/100 kcal) at the time of data collection (n = 5 oral calorie supplements; n = 5 enteral tube feeding; n = 1 multivitamin; n = 2 food fortification; n = 1 enteral and parenteral nutrition). Median (IQR) time on nutrition support was 1.8 days (0.0-8.6). Table I shows the prevalence of deficient and insufficient vitamin D results in both control group and childhood cancer group according diagnostic group and nutrition support status.
Twenty (49%) patients provided summer samples and 21 (52%) provided winter samples, and none provided both.The median (IQR) plasma 25(OH) D in the childhood cancer cohort was 37.0 nmol/l (23.7-58.2) and 27 patients (66%) were either vitamin D deficient or insufficient; 10 (24%) had vitamin D deficiency and 17 (42%) were classified as having insufficient results. In the childhood cancer group, there were no statistical significant (p > 0.05) differences between plasma vitamin D levels and the following variables: diagnostic groups (p > 0.05) (Table I); summer (median 40.0, IQR 31.0-70.5) and winter plasma 25(OH) D (nmol/l) (median 37.0, IQR 19.0-51.5). Finally there were no statistically significant differences between patients receiving nut support and those who were not (p > 0.05).
      Median (IQR) Deficient
n (% of total diagnostic group)
n (% of total diagnostic group)
controls Cases n=31* 37.5 (29.0-58.0) 6 (18) 14 (24)
Childhood cancer Cases n=41* 37 (23.7-58.2) 10 (24) 17 (41)
Diagnostic group Solid n=23** 35.0 (16.0-60.0) 6 (29) 8 (38)
Haematological n=18** 38.0 (27.7-52.2) 4 (22) 9 (50)
NS Not on NS n=27*** 36.0 (23.0-58.0) 8 (44) 10 (55)
On NS n=14*** 39.0 (29.7-62.5) 2 (22) 7 (77)
Table 1: Plasma 25(OH) D results and prevalence of vitamin deficiency and insufficient at recruitment according to group, gender and nutrition support (NS).
Thirty-three control samples were obtained. Seventeen (51%) controls provided winter samples 6 (18%) controls provided winter and summer samples and 10 (30%) provided summer only. The median (IQR) plasma 25(OH) D in the control group was 37.5 nmol/l (29.0-58.0). 20 participants (60%) were either vitamin D deficient or insufficient; 6 (18%) had vitamin D deficiency and 14 (42%) were classified as having insufficient plasma 25(OH) D. There was a significant difference (p < 0.05) between the plasma 25(OH) D (nmol/l) during summer months (median 56.5, IQR 45.5-78.0) and winter months (median 26.0, IQR 18.0-46.5.5). Plasma 25(OH) D was not significantly different between the healthy controls and the childhood cancer patients as a whole, according to season or when broken down into diagnostic groups (p > 0.05 for all).
Figure 2 and 3 shows the plasma PTH, calcium, phosphate and magnesium levels according to diagnostic group and the control. PTH was available for 38 patients (median 3.3 pg/ml; IQR 2.2-4.6)(Figure 2). Of all the patients with vitamin D deficiency at recruitment (n = 10), 30% (n = 3) had secondary hyperparathyroidism. There was no statistical significant correlation between PTH and 25(OH) D variables (p > 0.05; r = 0.18) in those patients with 25(OH) D < 50 nmol/l. Three patients with vitamin D insufficiency had low plasma PTH. In the control group one patient with vitamin D insufficiency had low plasma PTH.
Figure 2: PTH levels at recruitment according to diagnostic group (p > 0.05 for all).
Figure 3: Plasma calcium, phosphate and magnesium levels at recruitment according to diagnostic group (p > 0.05 for all).
Given the role of vitamin D in calcium absorption and metabolism, calcium was also measured. Median (IQR) plasma calcium was 2.3 mmol/l (2.1-2.3). Of the patients with solid and haematological cancers, 17% (n = 4) and 27% (n = 5) respectively, had hypocalcaemia upon recruitment. Comparison between groups was not possible because of the difference in age ranges and the small sample size. Six patients with either insufficient or deficient plasma 25(OH) D had hypocalcaemia below the normal ranges (Figure 3). Hypophosphataemia can be caused by vitamin D deficiency therefore plasma phosphate was assessed. Median (IQR) plasma phosphate was 1.3 mmol/l (1.1-1.5). Plasma phosphate (mmol/l) was below normal ranges in 22% (n = 5) patients in the solid group and 10% (n = 17) in the haematological group (Figure 3). Although there was no significant correlation between plasma phosphate and 25(OH) D (p > 0.05) at any point in time, 2 patients with low plasma 25(OH) D had also hypophosphatemia. Median (IQR) plasma magnesium was 0.86 (0.79-0.93). Plasma magnesium was below normal ranges for only 1 (6%) patient in the haematological group. Plasma calcium, phosphate and magnesium were within normal ranges for the control group (Figure 3).
This case-control study has shown a high prevalence of deficiency and insufficiency serum 25 (OH) D in newly diagnosed childhood cancer patients. However, the vitamin D status of the childhood cancer patients was comparable to that of the healthy controls from the same population. These findings suggest that newly diagnosed cancer patients in high latitudes in the Northern hemisphere such as Scotland are at no higher risk of poor vitamin D status than healthy children from the same geographical area.
Remarkably, this study did not indicate any seasonal differences in plasma vitamin D in the childhood cancer cohort, unlike that observed in the healthy controls, and as has been reported elsewhere [17]. In healthy populations, plasma 25(OH) D concentrations show a marked seasonal variation, being lowest during winter and highest during summer [16]. In the UK, the population relies on body stores and dietary vitamin D to maintain vitamin D status during winter months. These findings support the idea that children in the period prior to diagnosis and during cancer treatment do not have enough sun exposure to allow vitamin D synthesis. Therefore, it highlights the inability of the child to replenish their vitamin D stores during the summer months and the resulting importance of dietary sources to meet vitamin D requirements in this cohort.
It is important to note that the proportion of winter samples in the controls was higher compared to the childhood cancer group (30% vs 51%) which may have affected the results causing an increased risk of poor vitamin D status in the control group.
Although plasma level between patients receiving nutrition support and those who were not were comparable, the prevalence of vitamin D deficiency was higher in the non-nutrition support group. However, considering the limited sample size and the small length of nutrition support treatment, it is not possible to draw any conclusion on the role of nutrition support supplementing vitamin D and vitamin D status.
This study showed that vitamin D deficiency was associated with secondary hyperparathyroidism in some patients in the childhood cancer. If left untreated, secondary hyperparathyroidism can lead to severe clinical problems such as osteomalacia and rickets, so longitudinal monitoring during cancer treatment and eventual supplementation vitamin D is essential to minimise bone mass loss and optimise children’s and adolescents’ growth.
A limitation of this study is that some children were already on treatment at the time of blood sampling. However the very short course of treatment at the time of sampling is unlikely to have affected vitamin D status.
Although the results have not shown a specific increased risk in the childhood cancer patients at diagnosis, plasma vitamin D has been reported to be insufficient in acute lymphoblastic leukaemia (ALL) patients [5,6,18,19] and solid tumours patients at both diagnosis [5,6,18,19] and in remission phase [6,11,17].
Halton and co-workers [5] in a study conducted in Ontario, Canada (43.2°N), observed vitamin D plasma levels below normal range in 70% of children (n = 40) treated for ALL at both diagnosis, and after one year of treatment. A lower prevalence of plasma vitamin D deficiency has been reported in another study conducted in Rotterdam, Netherland (51.9°N) [20], where only 20% and 4.5% of ALL patients (n=61) had decreased plasma vitamin D at diagnosis and during therapy respectively. Moreover, some literature suggests an increased risk for poor vitamin D status in haematological patients after treatment [19] which highlights the possible detrimental effect of steroid therapy on vitamin D status [14] This would put this group of patients at even higher risk of vitamin D deficiency than their solid tumour counterparts.
The difference in the findings compared to the literature may be explained by the latitude of the countries where the studies were conducted. The study centre being more southerly than the others [5,20] may have led to an increased poor vitamin D status for both patients and controls.
 As discussed, it is plausible that childhood cancer patients are not exposed to sun light, even before diagnosis, due to the debilitating effects of undiagnosed disease and then side effects of treatments. Moreover, it is unlikely that the diet adequately compensates for the luck of sun exposure, considering the limited sources of dietary vitamin D and the poor nutritional status during cancer therapy. Therefore, considering the increased risk of poor vitamin D status in the high latitude countries, the well-known increased risk of vitamin D deficiency during cancer therapy and the need to sustain growth and development during childhood cancer therapy, monitoring of vitamin D status from diagnosis and eventual supplementation may be essential, particularly in those countries at high latitudes.
 Although these findings and the literature suggest the need for screening and potential supplementation of vitamin D, the efficacy and the safety of vitamin D supplementation to improve vitamin D status in children treated for cancer has not yet been proven. In a study [19] carried out in 40 patients affected by ALL and solid tumours, vitamin D supplementation was reported to improve vitamin D status in all patients apart from the haematological group. This differential response to vitamin D supplementation observed among the diagnostic groups may be explained by the increased vitamin D catabolism in ALL patients consequent to steroid therapy [13].
However, pharmacological doses given for a prolonged period of time may lead to increased plasma 25 (OH) D accompanied by hypercalcaemia. It has been shown that patients with granuloma forming diseases might develop vitamin D toxicity witnessed by hypercalcaemia at relatively low plasma 25(OH) D as a consequence of unregulated 1,25(OH) 2D production [21,22]. Therefore, it has been suggested [23] that pharmacological doses should be not prescribed to this patients group. It is now pivotal to establish if the current guidelines for vitamin D supplementation for healthy children applies to the cancer patients with other types of malignancies. Future research should aim to assess nutritional status from diagnosis throughout the treatments and monitor the changes in vitamin D status in response to supplementation according to specific treatments protocols and childhood cancer diagnosis.
This study demonstrated that newly diagnosed high latitude (Scottish) childhood cancer patients have a poor vitamin D status. However, the prevalence of low plasma vitamin D was comparable to the healthy controls. Extended longitudinal monitoring of vitamin D status in children with cancer should be considered, and supplementation likely needed. Furthermore, research is needed to clarify the role of nutrition supplementation and support in maintaining normal vitamin D status.
Conflict of Interest
JM and DCW have received research support from Danone Research BV. DCW has received speaker’s fees from SMA Nutrition, Nestle and SHS-Nutricia.
Source of funding
This project was funded by the Fergus Maclay Leukaemia Trust and by the GI-Nutrition Research fund of Child Life and Health, University of Edinburgh. The role of the Fergus Maclay Leukaemia Trust (a registered Scottish charity) was an unrestricted grant to support this investigator-initiated and investigator-led study. The role of the GI-Nutrition Research fund of Child Life and Health, University of Edinburgh (the University of Edinburgh is a registered Scottish charity) was to support some consumables and meeting travel not met by other sources. CB was funded by the Roald Dahl Marvellous Children’s Charity and the Burdett Trust for Nursing to carry out the study on Vitamin D in children with epilepsy -“Bone and Brains”.
Statement of Authorship
DCW designed the study; IP created the database; IP and RRI collected the data from the cancer patients; CB collected the control data; JM, MB and DCW supervised the study. IP and DCW prepared the manuscript with additions, comments and corrections by all the authors. All authors have read and approved the final draft. DCW is the guarantor of the article.
We would thank Prof. Hamish Wallace, Dr. Angela Thomas, Lindsay Archibald and Alison Gillies for their valuable input to the study.
  1. Holick MF. “High prevalence of vitamin D inadequacy and implications for health”. Mayo Clinic Proceedings 81.3 (2006): 353-373.
  2. Holick MF. “Resurrection of vitamin D deficiency and rickets”. JCI 116.8 (2006): 2062-2072.
  3. Sahota O., et al. “Hypovitaminosis D and 'functional hypoparathyroidism'-the NoNoF (Nottingham Neck of Femur) study”. Age Ageing 30.6 (2001): 467-472.
  4. Sahota O., et al. “Vitamin D insufficiency increases bone turnover markers and enhances bone loss at the hip in patients with established vertebral osteoporosis”. Clinical Endocrinology 51.2 (1999): 217-221.
  5. Halton JM., et al. “Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia”. Journal of Bone and Mineral Research 11.11 (1996): 1774-1783.
  6. R Revuelta Iniesta., et al. “Systematic review and meta-analysis: Prevalence and possible causes of vitamin D deficiency and insufficiency in pediatric cancer patients”. Clinical Nutrition (2015): S0261-5614.
  7. Arikoski P., et al. “Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: a 1-year prospective study”. Journal of Clinical Endocrinology & Metabolism 84.9 (1999): 3174-3181.
  8. Arikoski P., et al. “Disturbance in bone turnover in children with a malignancy at completion of chemotherapy”. Medical and Pediatric Oncology 33.5 (1999): 455-461.
  9. Choudhary A., et al. “Prevalence of vitamin D insufficiency in survivors of childhood cancer”. Pediatric Blood Cancer 60.7 (2013): 1237-1239.
  10. Bilariki K., et al. “Low bone mineral density and high incidences of fractures and vitamin D deficiency in 52 pediatric cancer survivors”. Hormone Research in Paediatrics 74.5 (2010): 319-327.
  11. Sinha A., et al. “Vitamin D status in paediatric oncology patients compared to control subjects: grounds for targeted supplementation”. Endocrine Abstracts 24 (2010): 43.
  12. Modan-Moses D., et al. “Vitamin D status in pediatric patients with a history of malignancy”. Pediatric Research 57.4 (2012): 620-624.
  13. Skversky AL., et al. “Association of glucocorticoid use and low 25-hydroxyvitamin D levels: results from the National Health and Nutrition Examination Survey (NHANES): 2001-2006”. Clinical Endocrinology Metabolism 96.12 (2011): 3838-3845.
  14. Zhou C., et al. “Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia”. Journal of Clinical Investigation 116.6 (2006): 1703-1712.
  15. Steliarova-Foucher E., et al. “International Classification of Childhood Cancer, third edition”. Cancer 103.7 (2005): 1457-1467.
  16. Lund B and Sorensen OH. “Measurement of 25-hydroxyvitamin D in serum and its relation to sunshine, age and vitamin D intake in the Danish population”. Scandinavian Journal of Clinical and Laboratory Investigation 39.1 (1979): 23-30.
  17. Frisk P., et al. “Decreased bone mineral density in young adults treated with SCT in childhood: the role of 25-hydroxyvitamin D”. Bone Marrow Transplant 47.5 (2012): 657-662.
  18. Sinha A., et al. “Vitamin D status in paediatric patients with cancer”. Pediatric Blood Cancer 57.4 (2011): 594-598.
  19. Helou MA., et al. “Vitamin D insufficiency in the pediatric oncology population: defining who is at risk and the need for standardized screening”. Journal of Clinical Oncology 26.20 suppl (2008): 723-728.
  20. van der Sluis IM., et al. “Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia”. Journal of Paediatrics 141.2 (2002): 204-210.
  21. Adams JS., et al. “Vitamin D in Defense of the Human Immune Response”. Annals of the New York Academy of Sciences 1117.1 (2007): 94-105.
  22. Kavathia D., et al. “Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis”. Respiratory Medicine 104.4 (2010): 564-570.
  23. Holick MF. “Vitamin D deficiency”. The New England Journal of Medicine 357.3 (2007): 266-281.
Copyright: © 2015 Ilenia Paciarotti., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

June Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the June issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before July 06, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to